pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Logistic regression of blood glucose and duration of pembrolizumab administration in (A) all patients and (B) patients of no history of diabetes and concomitant therapy (A) All patients (N= 133)

Factor OR (95% CI) p-value
Sex Male 1 (Reference) -
Female 1.03 (0.48-2.23) 0.932
Age, years 1.01 (0.98-1.04) 0.609
Weight, kg 1.00 (0.96-1.03) 0.684
BMI, kg/m2 1.01 (0.91-1.11) 0.893
BMI, kg/m2 (categorized) Underweight (<18.5) 2.06 (0.63-7.04) 0.232
Normal (≥18.5, <23) 1 (Reference) -
Overweight (≥23, <25) 1.66 (0.66-4.25) 0.281
Obese (≥25) 1.55 (0.66-3.63) 0.313
Cancer type Lung 1 (Reference) -
Melanoma 1.53 (0.57-4.18) 0.399
Others 1.1(0.48-2.51) 0.815
Baseline blood glucose, mg/dL < 130 3.82 (1.84-8.23) < 0.001
≥ 130 1 (Reference) -
History of diabetes Yes 1.1 (0.49-2.46) 0.821
No 1 (Reference) -
Treatment of diabetes Yes 0.9 (0.38-2.1) 0.8
No 1 (Reference) -
Concomitant steroid therapy No 1 (Reference) -
Prophylactic 1.44 (0.61-3.46) 0.405
Intervention 0.96 (0.37-2.44) 0.934
Number of cycles for 100 days 1.0 (0.96-1.04) 0.962
Cumulative dose for 100 days, mg 1.0 (1.0-1.0) 0.207
Cumulative dose for 100 days, dose/kg 0.96 (0.88-1.05) 0.414
Mean dose per cycle for 100 days, mg/kg/cycle 1.21 (0.77-1.91) 0.402
Korean J Clin Pharm 2021;31:237-46 https://doi.org/10.24304/kjcp.2021.31.3.237
© 2021 Korean J Clin Pharm